lysergic acid diethylamide has been researched along with Disease Models, Animal in 31 studies
Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 5.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| "The difficulties in assessing the teratogenic potential of drugs used during pregnancy have been made evident by experiences with thalidomide and diethylstilbestrol (DES)." | 4.76 | In vivo assessment of the teratogenic potential of drugs in humans. ( Stern, L, 1981) |
| " In contrast to the primary hypothesis, psychedelics had no long-lasting effects on the ADE in male and female rats, neither when administered in a high dosage regime that is comparable to the one used in clinical studies, nor in a chronic microdosing scheme." | 1.56 | Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse. ( Güngör, C; Meinhardt, MW; Mertens, LJ; Skorodumov, I; Spanagel, R, 2020) |
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 1.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| " There were no significant interactions between LSD treatment and Sert gene dosage in any of the behavioral domains measured." | 1.43 | Effects of LSD on grooming behavior in serotonin transporter heterozygous (Sert⁺/⁻) mice. ( Kalueff, AV; Kyzar, EJ; Stewart, AM, 2016) |
| " Chronic administration of low doses of LSD (>3 months, 0." | 1.37 | An animal model of schizophrenia based on chronic LSD administration: old idea, new results. ( Marona-Lewicka, D; Nichols, CD; Nichols, DE, 2011) |
| "5." | 1.28 | LSD and other related hallucinogens elicit myoclonic jumping behavior in the guinea pig. ( Carvey, P; Klawans, H; Nausieda, P; Weertz, R, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (61.29) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 1 (3.23) | 29.6817 |
| 2010's | 7 (22.58) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Meinhardt, MW | 1 |
| Güngör, C | 1 |
| Skorodumov, I | 1 |
| Mertens, LJ | 1 |
| Spanagel, R | 1 |
| de Abreu, MS | 1 |
| Giacomini, ACVV | 1 |
| Demin, KA | 1 |
| Galstyan, DS | 1 |
| Zabegalov, KN | 1 |
| Kolesnikova, TO | 1 |
| Amstislavskaya, TG | 1 |
| Strekalova, T | 1 |
| Petersen, EV | 1 |
| Kalueff, AV | 2 |
| De Gregorio, D | 2 |
| McLaughlin, RJ | 1 |
| Posa, L | 2 |
| Ochoa-Sanchez, R | 1 |
| Enns, J | 1 |
| Lopez-Canul, M | 1 |
| Aboud, M | 1 |
| Maione, S | 1 |
| Comai, S | 2 |
| Gobbi, G | 2 |
| Buchborn, T | 1 |
| Schröder, H | 1 |
| Höllt, V | 1 |
| Grecksch, G | 1 |
| Yamazaki, M | 1 |
| Okabe, M | 1 |
| Yamamoto, N | 1 |
| Yarimizu, J | 1 |
| Harada, K | 1 |
| Kyzar, EJ | 1 |
| Stewart, AM | 1 |
| Marona-Lewicka, D | 1 |
| Nichols, CD | 1 |
| Nichols, DE | 1 |
| Moreno, JL | 1 |
| Holloway, T | 1 |
| Umali, A | 1 |
| Rayannavar, V | 1 |
| Sealfon, SC | 1 |
| González-Maeso, J | 1 |
| Arvanian, VL | 1 |
| Manuzon, H | 1 |
| Davenport, M | 1 |
| Bushell, G | 1 |
| Mendell, LM | 1 |
| Robinson, JK | 1 |
| Morgenstern, R | 1 |
| Fink, H | 1 |
| Oelssner, W | 2 |
| Stern, L | 1 |
| Braff, DL | 1 |
| Geyer, MA | 2 |
| Marini, JL | 1 |
| Sheard, MH | 1 |
| Carlsson, ML | 1 |
| Schwarcz, R | 1 |
| Bennett, JP | 1 |
| Coyle, JT | 1 |
| Claridge, G | 1 |
| Heath, RG | 1 |
| Carvey, P | 1 |
| Nausieda, P | 1 |
| Weertz, R | 1 |
| Klawans, H | 1 |
| Colpaert, FC | 1 |
| Meert, TF | 1 |
| Niemegeers, CJ | 1 |
| Janssen, PA | 1 |
| Cadet, JL | 1 |
| Kuyatt, B | 1 |
| Fahn, S | 1 |
| De Souza, EB | 1 |
| Adams, LM | 1 |
| Krsiak, M | 1 |
| Gillin, JC | 1 |
| Cannon, E | 1 |
| Magyar, R | 1 |
| Schwartz, M | 1 |
| Wyatt, RJ | 1 |
| Fog, R | 1 |
| Amarose, AP | 1 |
| Schuster, CR | 1 |
| Muller, TP | 1 |
| Kato, T | 1 |
| Jarvik, LF | 1 |
| Roizin, L | 1 |
| Moralishvili, E | 1 |
| Naquet, R | 1 |
| O-Ishi, S | 1 |
| Sakuma, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet[NCT04088929] | Phase 2 | 32 participants (Actual) | Interventional | 2019-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT04679545] | Phase 2 | 50 participants (Anticipated) | Interventional | 2020-12-10 | Recruiting | ||
| Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury[NCT04057456] | Phase 3 | 140 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT05766969] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for lysergic acid diethylamide and Disease Models, Animal
| Article | Year |
|---|---|
Unconventional anxiety pharmacology in zebrafish: Drugs beyond traditional anxiogenic and anxiolytic spectra.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aspirin; Behavior, Animal; Disease Models, Animal; Humans; Ly | 2021 |
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dorsal Raphe Nucl | 2016 |
In vivo assessment of the teratogenic potential of drugs in humans.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Animals; Cannabis; Diethylstilbestrol; Disease Model | 1981 |
On stereotypy and catalepsy: studies on the effect of amphetamines and neuroleptics in rats.
Topics: Amphetamine; Animals; Basal Ganglia; Caffeine; Catalepsy; Cocaine; Compulsive Behavior; Corpus Stria | 1972 |
27 other studies available for lysergic acid diethylamide and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse.
Topics: Animals; Disease Models, Animal; Female; Hallucinogens; Lysergic Acid Diethylamide; Male; Psilocybin | 2020 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Behavior, Animal; Depression; Disease Models, An | 2014 |
Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats.
Topics: Aging; Animals; Brain; Cognition Disorders; Dementia; Disease Models, Animal; Dose-Response Relation | 2015 |
Effects of LSD on grooming behavior in serotonin transporter heterozygous (Sert⁺/⁻) mice.
Topics: Animals; Disease Models, Animal; Grooming; Lysergic Acid Diethylamide; Male; Mice; Mice, Inbred C57B | 2016 |
An animal model of schizophrenia based on chronic LSD administration: old idea, new results.
Topics: Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; DN | 2011 |
Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Down-Regulation; | 2013 |
Combined treatment with neurotrophin-3 and LSD facilitates behavioral recovery from double-hemisection spinal injury in neonatal rats.
Topics: Animals; Animals, Newborn; Denervation; Disease Models, Animal; Drug Combinations; Drug Synergism; D | 2006 |
LSD-potentiated apomorphine hypermotility: a model for differentiating antipsychotic drugs.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Disease Models, Animal; Drug Antagonism; Haloperido | 1983 |
[Hallucinogen caused motility disorders in rats as potential psychosis relevant animal model].
Topics: Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dru | 1982 |
Acute and chronic LSD effects on rat startle: data supporting an LSD--rat model of schizophrenia.
Topics: Animals; Disease Models, Animal; Drug Tolerance; Humans; Lysergic Acid Diethylamide; Male; Rats; Ref | 1980 |
On the specificity of a cat behavior model for the study of hallucinogens.
Topics: Animals; Behavior, Animal; Cats; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Tole | 1981 |
The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis.
Topics: Animals; Biogenic Monoamines; Disease Models, Animal; Dizocilpine Maleate; Dopamine Uptake Inhibitor | 1995 |
Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's Disease.
Topics: Animals; Caudate Nucleus; Disease Models, Animal; Humans; Huntington Disease; Lysergic Acid Diethyla | 1977 |
Animal models of schizophrenia: the case for LSD-25.
Topics: Animals; Arousal; Attention; Brain; Discrimination Learning; Disease Models, Animal; Galvanic Skin R | 1978 |
Brain function in epilepsy: midbrain, medullary, and cerebellar interaction with the rostral forebrain.
Topics: Animals; Brain; Cerebellum; Cerebral Cortex; Cobalt; Disease Models, Animal; Electric Stimulation; E | 1976 |
LSD and other related hallucinogens elicit myoclonic jumping behavior in the guinea pig.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Tolerance; Guinea Pigs; Hall | 1989 |
Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat.
Topics: 5-Hydroxytryptophan; Animals; Anti-Anxiety Agents; Anxiety; Chlordiazepoxide; Diazepam; Disease Mode | 1985 |
Differential changes in 125I-LSD-labeled 5-HT-2 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN): evidence from autoradiographic studies.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Iodine Radioisotopes; Lysergic Acid Diethy | 1987 |
Effects of DOM and DMT in a proposed animal model of hallucinogenic activity.
Topics: Amphetamines; Animals; Cyproheptadine; Disease Models, Animal; DOM 2,5-Dimethoxy-4-Methylamphetamine | 1985 |
Proceedings: Isolation-induced timidity in mice as a measure of anxiolytic activity of drugs.
Topics: Animals; Anxiety Disorders; Barbiturates; Chlordiazepoxide; Chlorpromazine; Dextroamphetamine; Diaze | 1974 |
Failure of N,N-dimethyltryptamine to evoke tolerance in cats.
Topics: Animals; Behavior, Animal; Cats; Disease Models, Animal; Drug Tolerance; Electroencephalography; Hal | 1973 |
An animal model for the evaluation of drug-induced chromosome damage.
Topics: Animals; Chromosome Aberrations; Chromosomes; Disease Models, Animal; Fever; Lysergic Acid Diethylam | 1973 |
Chromosome studies in pregnant rhesus macaque given LSD-25.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Chromosome Aberrations; Chromosome Disorders | 1970 |
Photosensitive epilepsy of the baboon Papio papio.
Topics: Animals; Disease Models, Animal; Electroencephalography; Epilepsy; Isoniazid; Light; Lysergic Acid D | 1972 |
A model for rat paw edema. II. Analyses on the effect of the antagonists.
Topics: Amino Alcohols; Animals; Anti-Inflammatory Agents; Bradykinin; Bromelains; Carbamates; Carrageenan; | 1970 |